Recent advances in uveitis therapy: focus on selected phase 2 and 3 clinical trials.
Zheng Xian ThngAlbert John BromeoS Saeed MohammadiAnadi KhatriAnh N T TranAmir AkhavanrezayatNgoc T T ThanKhiem S NguyenSeong Jae KimAzadeh MobasserianChristopher Chi Mong OrQuan Dong NguyenPublished in: Expert opinion on emerging drugs (2023)
There has been incredible growth in the number of treatment options available to uveitis patients today, especially with the new generation of biologic drugs. Available evidence suggests that these newer options may be superior to conventional immunosuppressive therapies in terms of efficacy and side effect profiles. Further high-quality research and additional clinical trials will be needed to clarify their roles in the stepladder treatment approach of noninfectious uveitis.
Keyphrases
- clinical trial
- juvenile idiopathic arthritis
- ankylosing spondylitis
- end stage renal disease
- rheumatoid arthritis
- chronic kidney disease
- ejection fraction
- newly diagnosed
- prognostic factors
- phase ii
- stem cells
- randomized controlled trial
- disease activity
- patient reported outcomes
- mesenchymal stem cells
- patient reported
- study protocol